# Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Source: https://onco.cc/trials/nct00880269/  
OnCo record `nct00880269` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Panobinostat in Leukaemia, run by Novartis Pharmaceuticals, completed.

## Summary

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) is a phase 2 interventional study registered as NCT00880269 by Novartis Pharmaceuticals, with 59 participants recorded, started 2009-08 and reaching its primary completion in 2012-02. Interventions recorded: Panobinostat/LBH589. Conditions recorded: Refractory Leukemia, Acute Myelogenous Leukemia.

Linked to the drug Panobinostat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00880269
- Phase: 2
- Setting: A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 59

## Sources

- ClinicalTrials.gov NCT00880269: https://clinicaltrials.gov/study/NCT00880269

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Panobinostat](https://onco.cc/drugs/panobinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct00880269.json